Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 31, Issue 9, 2004, Pages 1727-1731

  Kent, Peter D ^a,b   Luthra, Harvinder S ^a,b   Michet Jr , Clement J ^a,b  

^a MAYO CLINIC   (United States)

^b Department of Medicine ^*  (United States)

Author keywords

Drug monitoring; Methotrexate; Rheumatoid arthritis; Risk factors

Indexed keywords

ASPARTATE AMINOTRANSFERASE; FOLIC ACID; METHOTREXATE;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD CELL COUNT; BODY MASS; DRUG MONITORING; FATTY LIVER; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPOALBUMINEMIA; LABORATORY TEST; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OBESITY; PATIENT MONITORING; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VITAMIN SUPPLEMENTATION;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ASPARTATE AMINOTRANSFERASES; COHORT STUDIES; FEMALE; FOLIC ACID; HUMANS; HYPERLIPIDEMIAS; INCIDENCE; LIVER CIRRHOSIS; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 4444369382     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Kremer J, Alarcon GS, Lightfoot RW Jr., et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994;37:316-28.
2. Kremer JM, Lee RG, Tolman KG. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples. Arthritis Rheum 1989;32:121-77.
3. Kremer JM, Glaivan J, Streckfuss A, Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 1986;29:832-5.
4. Shergy WJ, Polisson RP, Caldwell DS, Rice JR, Pisetsky DS, Allen NB. Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. Am J Med 1988;85:771-4.
5. Walker AM, Funch D, Dreyer NA, et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 1993;36:329-35.
6. Coleiro B, Mallia C. Toxicity profile of methotrexate in rheumatoid arthritis. A preliminary study. Adv Exp Med Biol 1999;455:359-65.
7. Weinblatt ME, Fraser P. Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheum 1989;32:1592-6.
8. Kremer Jm, Furst DE, Weinblatt ME, Blotner SD. Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. J Rheumatol 1996;23:459-61.
9. Van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001;44:1515-24.
10. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2003;346:1221-31.
11. Langman G, Hall PM, Todd G. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol 2001;16:1395-401.
12. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis [letter]. J Hepatol 1999;31:384.
13. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-9.